Mercados españoles cerrados

Santen Pharmaceutical Co., Ltd. (SNPHF)

Other OTC - Other OTC Precio demorado. Divisa en USD
Añadir a la lista de favoritos
9,740,00 (0,00%)
Al cierre: 12:15PM EST

Santen Pharmaceutical Co., Ltd.

Grand Front Osaka Tower A
4-20 Ofuka-cho Kita-ku
Osaka 530-8552
Japan
81 6 7664 8621
https://www.santen.com

Sector(es)Healthcare
SectorDrug Manufacturers - General
Empleados a tiempo completo4144

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Takeshi ItoPresident, CEO & Representative DirectorN/AN/A1959
Mr. Kazuo KoshijiChief Financial Officer & Chief Risk OfficerN/AN/AN/A
Ms. Rie NakajimaCOO & Corporate OfficerN/AN/AN/A
Mr. Minori HaraChief Digital & Information OfficerN/AN/AN/A
Ms. Kaori ItagakiGeneral Manager of Investor Relations GroupN/AN/AN/A
Ms. Mika MasunariGeneral Counsel & Chief Compliance OfficerN/AN/AN/A
Ms. Nobuko KatoChief Communications OfficerN/AN/AN/A
Mr. Satoshi SuzukiSenior Corporate Officer & Head of Corporate Development Division & DirectorN/AN/A1963
Mr. Shinichi TeramachiCorporate Officer, Head of Sales Department & Japan Sales and Marketing DivisionN/AN/AN/A
Mr. Ippei KuriharaCorporate Officer and Head of Marketing Department, Japan Business, Japan Sales & Marketing DivisionN/AN/AN/A
Los importes son a partir de y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.

Gobierno corporativo

El ISS Governance QualityScore de Santen Pharmaceutical Co., Ltd., a día 1 de marzo de 2024, es 2. Las puntuaciones base son Auditoría: 1; Tablero: 3; Derechos de los accionistas: 2; Compensación: 1.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.